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Abbreviations
CHF Congestive heart failure
ECG Electrocardiogram
HFNEF Heart failure with normal ejection fraction
HRV Heart rate variability
ICD Implantable cardioverter defibrillator
LVEF Left ventricular ejection fraction
MI Myocardial infarction
NYHA New York Heart Association
SAECG Signal-averaged electrocardiogram
SCD Sudden cardiac death
VT Ventricular tachycardia
The recognition that severe left ventricular dysfunction is a
predictor of sudden cardiac death (SCD) risk enabled
widespread utilization of the implantable cardioverter
defibrillator (ICD) for SCD prevention. Use of the ICD
prior to any signs or symptoms of ventricular arrhythmias
(“primary prevention”) is particularly important for SCD
because case fatality for patients with sustained ventricular
tachyarrhythmias is among the highest of any disease
process. At the same time, primary prevention of SCD
presents a unique epidemiologic challenge for many
reasons [1, 2]: (1) high-risk subgroups constitute only a
small proportion of all patients at risk for SCD, (2) the
pathophysiologic etiologies of SCD are complex and
infrequently recognized prior to arrest, (3) ventricular
arrhythmia substrate often evolves over time and may
require repeated risk stratification, (4) classification of
arrhythmic death is particularly imprecise, (5) triggers for
SCD may be transient, and (6) patients at high risk for SCD
have many competing risks that are not ameliorated by
ICDs. This review will address the limitations of risk
stratification based on left ventricular ejection fraction
(LVEF), summarize new developments in the field that
extend beyond LVEF, and suggest new investigative
approaches for refinement of SCD risk assessment.
1 The promise of LVEF-based prevention efforts
Two early trials, MADIT-I and Multicenter Unsustained
Tachycardia Trial (MUSTT), established the role of ICDs
for primary prevention of SCD based on impaired LVEF and
positive electrophysiology study [3, 4]. Subsequent trials,
Multicenter Automatic Defibrillator Implantation Trial II
(MADIT-II) and Sudden Cardiac Death in Heart Failure Trial
(SCD-HEFT), used LVEF without additional high-risk
markers for ventricular arrhythmia. MADIT-II enrolled
1,232 patients with prior myocardial infarction (MI) and
New York Heart Association (NYHA) class I, II, or III, and
randomized to ICD versus conventional medical therapy [5].
SCD-HEFT enrolled 2,521 patients with ischemic or non-
ischemic cardiomyopathy and NYHA class II or III conges-
tive heart failure (CHF) and randomized to ICD, amiodarone,
or placebo [6]. MADIT-II survival curves showed a 31%
reduction in risk of death (5.6% absolute risk reduction at
20-month mean follow-up), while SCD-HEFT showed a 23%
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(7.2% absolute risk reduction at 5-year follow-up). There was
no benefit of amiodarone as compared to placebo.
2 Limitations of LVEF-based prevention efforts
It quickly became evident that a significant number of patients
who receive an ICD under MADIT-II or SCD-HEFT criteria
do notbenefit from it duringintermediate-term follow-up of 2–
5 years [7]. During the 20-month average follow-up of
MADIT-II, the annualized rate of appropriate ICD therapies
was 17% [8]. Over 5 years of follow-up in SCD-HEFT, the
annualized rate of appropriate therapies was 5.1% [6].
Differences in patient populations likely were notable
contributors to the disparate rates of ICD utilization.
Consistent between both studies was a lack of benefit
observed at the upper range of the LVEF limit for enrollment
[1]. At the same time that many ICDs go unutilized, a
majority of patients at risk for cardiac arrest do not qualify for
an ICD despite the broadened LVEF-based indications
(conceptually illustrated in Fig. 1 and in Table 1). Two
population based studies in the Netherlands (Maastricht
study) and Oregon, USA (The Oregon Sudden Unexpected
Death Study), have demonstrated that the majority of patients
who suffer SCD do not have a severely reduced LVEF. In
subsets with medical history available, only 20–30% of
patients who suffered SCD had LVEF low enough to have
warranted primary prevention of SCD with an ICD [9–11].
Two conclusions can be drawn about current practices
for primary prevention ICD use:
1. Even at the higher 17% annualized utilization rates
from MADIT-II, there is considerable room for im-
provement in patient selection if new risk stratification
methods can be developed.
2. LVEF-based prevention efforts will miss a majority of
SCD patients. At the same time, the incidence of SCD
among patients in the general population who have
normal LVEF is so low that powerful risk stratification
schemes will be necessary to define patients at high
enough risk to receive an ICD (Table 1).
3 Limitations of existing non-LVEF risk predictors
A number of non-LVEF risk stratification tests have been
evaluated individually for relevance in predicting a variety of
outcomes (overallmortality, arrhythmicevents/mortality, ICD
shocks, and mortality benefit from ICDs). These tests include
signal-averaged ECG, QRS duration, QT interval, ventricular
ectopy, heart rate variability, heart rate turbulence, exercise
capacity, heart failure class, heart rate recovery or ventricular
ectopy after exercise, T-wave alternans, baroreceptor sensi-
tivity, and electrophysiology study with ventricular
programmed ventricular stimulation (many summarized in
Table 2)[ 12, 13]. Clinical applicability has been limited thus
far because most studies have not demonstrated sufficiently
high predictive value for arrhythmic death or arrhythmic
events [12]. Five were considered promising enough to be
tested for their ability to predict mortality benefit from ICD
use in the context of randomized trials. The first two, non-
sustained ventricular tachycardia (VT) on ambulatory ECG
and inducible VT during electrophysiology study, were
effective in defining patients with severe ischemic cardio-
myopathy who are at very high risk of SCD and benefit from
an ICD [3, 4]; however, the SCD risk among patients
without these markers was still uncomfortably high for
patients with severely reduced LVEF, prompting subsequent
trials without these predictors [5, 6]. The third non-LVEF
risk stratifier, abnormal signal-averaged ECG (SAECG), was
Fig. 1 Venn diagrams of primary prevention and secondary preven-
tion ICD utilization strategies, (a) shows the current approach, with a
majority of SCD victims not previously qualifying for an ICD and
many ICDs unutilized, and (b) shows an idealized approach with
fewer cases of SCD due to fewer at-risk patients (from coronary artery
disease prevention efforts) and more efficient utilization of ICDs
among at-risk patients. LVEF left ventricular ejection fraction, SCD
sudden cardiac arrest, ICD implantable cardioverter defibrillator
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Although SAECG had shown initial promise, there was no
benefit from ICD implantation in this trial. The fourth
predictor, heart rate variability on 24-h Holter, was tested as
an entry criterion for the Defibrillator in Acute Myocardial
Infarction Trial (DINAMIT) of ICD placement within 6 to
40 days of MI in patients with LVEF ≤35% [15]. This trial
also showed no benefit. The fifth predictor, microvolt T-
wave alternans, has shown some promise, but when tested in
the setting of primary prevention ICD use as part of SCD-
HeFT, it was not predictive of arrhythmic events [16].
4 Identification of novel non-LVEF risk predictors
Novel risk prediction methods are acutely needed to more
efficiently utilize ICDs for SCD prevention. We currently
spend approximately $3.6 billion dollars annually on ICDs
in the US (113,000 annual implants [17] with an assumed
cost per implant of $33,000 [18]) with a large majority of
devices unutilized. At the same time, current ICD guide-
lines do not address half of patients who will experience
SCD [11]. We believe effective and efficient SCD preven-
tion will require two simultaneous efforts:
4.1 Refine existing criteria for ICD-based primary
prevention using clinical risk scores
Risk scores have been used to retrospectively define benefit
or lack of benefit from primary prevention ICD use.
Investigators from the MUSTT study identified EF-
independent predictors of total and arrhythmic mortality
among patients with LVEF ≤40% after MI who were
assigned to the no-antiarrhythmic drug/no-ICD arm [19].
The MADIT-II investigators derived a risk score based on
patient data from MADIT-II and compared the mortality
rates for ICD or conventional therapy at different risk-score
levels [20]. Very low and very high mortality rate cohorts
did not benefit from ICDs, while intermediate risk cohorts
had a 49% risk reduction. SCD-HeFT patients were
similarly evaluated using a risk score modified from the
Seattle Heart Failure Model (SHFM-D) and derived in a
separate population [21]. Investigators evaluated ICD
benefit in each mortality quintile. Mortality risk reductions
for ICD therapy ranged from 31% to 54% in first four
quintiles, with no benefit in the highest risk quintile. The
absolute risk reductions were 7% to 14% in the first four
quintiles over nearly 4 years follow-up.
The MADIT-II and SHFM-D risk scores use non-invasive
data regarding co-mordibities, functional status, and labora-
tory values that could be easily utilized in clinical practice.
The MADIT-II score applies only to ischemic cardiomyopa-
thy patients, while the SHFM-D score from SCD-HeFT
applies to ischemic and non-ischemic cardiomyopathy
patients. The SHFM-D score has 15 predictor variables
(includingLVEF) while the MADIT-2score has fivepredictor
variables and was derived separately from the SCD-HeFT
validationpopulation.Bothstudiesshowthatpatientswiththe
highest overall mortality rates did not benefit from ICDs.
Itmaybe difficult for some physiciansandpatients tomove
toward withholding ICDs based on these risk scores because
they were not used as entry criteria for randomized controlled
trials. The uncertainty would be clarified by a randomized trial
designed to test non-inferiority of a strategy to withhold ICD
treatment based on risk score for specific patients with LVEF
≤35%. While there are challenges to theconduct of such a trial,
the cost of such a reseacheffort would beamore fractionofthe
current total annual ICD expenditures in the US. Even if this
researcheffort cost$100million,itwouldrepresent only3% of
total annual ICD expenditures in the US.
4.2 Define new high-risk, ICD-eligible patients
Develop new risk stratification tools from large unbiased
community-based evaluations where all-comers with SCD
are evaluated regardless of LVEF Additional novel risk
Table 1 Estimates of SCD incidence in Portland, Oregon metro area population (aged ≥45 years)
Ejection fraction Percent of population Percent of SCDs SCD incidence rate
All 100% 100% 142/100,000
LVEF ≤50% 5.8% 52% Greater than 1,000/100,000
LVEF >50% 94.2% 48% Less than 100/100,000
The SCD incidence among patients with normal LVEF is very small, yet accounts for almost half of all SCD cases. This illustrates that in order to
significantly impact the overall problem of SCD, prevention efforts must focus beyond LVEF. Estimates in this table should be used for general
descriptive purposes only. We generated estimates of SCD incidence rates for normal versus abnormal LVEF by using results from the population-
based Rochester Epidemiology Project [35] and applying to the same age distribution for the population-based Oregon Sudden Unexpected Death
Study [10]. We assumed that the LVEF distribution for SCD patients with prior LVEF assessment applied to all patients with SCD [11]. Because
of these extrapolations, we have reported ranges of SCD incidence for LVEF subcategories rather than the calculated SCD point incidence because
such an incidence would have precision highly disproportionate to its level of accuracy. LVEF left ventricular ejection fraction, SCD sudden
cardiac arrest, ICD implantable cardioverter defibrillator
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tion, etc.) could be identified from large community-based
studies that collect SCD patients who have a broad range of
LVEF. For example, genome-wide association studies
performed in the community can yield novel genetic
variations that confer protectiveness [22]a sw e l la s
susceptibility [23] to SCD. Biomarkers such as C-reactive
protein, B-natriuretic peptide, and fatty acid levels have
been associated with SCD risk [22]. Cardiac imaging
techniques have also shown promise. Nuclear imaging of
cardiac sympathetic nerve activity and perfusion may
identify a higher arrhythmia-risk substrate [24, 25]. Cardiac
magnetic resonance imaging (MRI) showing late gadolin-
ium enhancement (presence of scar) in patients with
ischemic cardiomyopathy appears highly predictive of
inducibility of sustained VT with programmed electrical
stimulation [26]. Among patients with non-ischemic cardio-
myopathy, the presence of late gadolinium enhancement on
cardiac MRI is predictive of a composite endpoint including
ICD discharges [27]. Studies of patients with hypertrophic
cardiomyopathy have shown correlation between presence of
LGE on cardiac MRI and markers of SCD risk or composite
endpoints including SCD [28–30]. New techniques for
evaluating interstitial fibrosis by MRI are undergoing
development and evaluation.
Because many genetic and clinical variables have odds
ratios or relative risk ratios of 2 or less, it will be important
to derive multiple independent variables from the same
population. Ultimately, these factors should be combined
into cost-efficient test panels.
Utilize existing and novel risk stratification methods to
identify patient populations with LVEF >35% whose
annual SCD rates are at least 5% Identifying groups with
annual SCD rates greater than 5% would identify patients at
higher risk than existing primary prevention ICD trials.
This would increase odds of efficient of ICD utilization in
subsequent trials. Risk scores using clinical factors,
biomarkers, and genetic factors can be tested retrospective-
ly in some large community-based cohorts or drug trial
cohorts when modes of death are well characterized and
blood/serum has been stored for subsequent analysis. Other
risk stratification tests will generally require evaluation
prospectively (e.g., imaging studies, novel electrocardio-
Table 2 Summary of existing non-LVEF risk stratification tests
Risk stratification tests Evidence for predicting SCD Evidence for predicting ICD-detected VT/VF
Programmed ventricular
stimulation
￿ Strong PPV in ischemic cardiomyopathy; also
proven to identify patients with large mortality
benefit from ICDs.
Strong PPV for ventricular arrhythmia risk in ischemic
cardiomyopathy.
￿ Limited negative predictive value in ischemic
cardiomyopathy with moderately to severely
reduced LVEF.
￿ Not predictive for other cardiomyopathy
etiologies.
QRS duration Mixed findings, MUSTT found it was
independently predictive while other studies
did not.
Preponderance of studies shows it is not independently
predictive.
QT interval Population-based and cohort data showing
independent prediction of SCD.
T-wave alternans Potentially promising technique, but several large cohort studies have shown limited PPVand not predictive in a large
randomized trial. Generally composite outcomes measured.
Signal-averaged ECG Limited to post-MI patients. Variable PPV and no
benefit for ICD implantation among positive test in
CABG-PATCH. Negative predictive value has
been >90%, though generally evaluated prior to
widespread reperfusion of AMI.
Heart rate variability
and baroreflex
sensitivity
Limited to post-MI patients. Aside from ATRAMI,
these markers have not discriminated sudden from
non-sudden death.
Cardiac MRI with late
gadolinium
enhancement imaging
Correlates with surrogate markers of SCD risk in patients
with ischemic, non-ischemic, and hypertrophic cardiomy-
opathies in small studies (n<200 for each study).
Several tests also predict all-cause mortality and/or cardiac events and mortality; only tests with purported or demonstrated preferential
discrimination for arrhythmic events and sudden cardiac death are addressed here. See also more detailed discussions of risk stratification tests
[12, 13]. LVEF left ventricular ejection fraction, SCD sudden cardiac arrest, ICD implantable cardioverter defibrillator, MI myocardial infarction,
MRI magnetic resonance imaging, PPV positive predictive value
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with high annual SCD rates, we must evaluate the ability of
ICDs to reduce all-cause mortality.
5 Translation of novel strategies into clinical practice
There are several pathophysiologically homogenous
cohorts with LVEF >35% that may be sufficiently high
risk to warrant randomized controlled trials of primary
prevention ICD use:
& Acute MI. Within the first 30 days after MI, 1.4% of
patients have SCD (annualized rate of 17% [31]). Two
randomized controlled trials, DINAMIT and Immediate
Risk-Stratification Improves Survival (IRIS), tested the
value of ICDs in patients in the first 40 days after MI
and showed no benefit [15, 32]. It is not clear whether
these negative trials resulted from excessive risk of non-
arrhythmic death during this time period, ventricular
arrhythmia that is less amenable to ICD termination
(due to recurrent acute infarction or pump failure), or
risk stratification methods that did not select patients at
sufficient risk for SCD. A large majority of patients in
DINAMIT and IRIS were selected based on impaired
LVEF combined with either impaired heart rate vari-
ability or elevated resting heart rate, both of which are
poor predictors of arrhythmic events. Alternative risk
stratification methods such as electrophysiology study
[33] and/or MRI [34] could yield patients with higher
arrhythmic event rates.
& Ischemic CM with LVEF >35%. Beyond the first month
after MI, the SCD rate drops rapidly and is lower for
patients with higher initial LVEF [31]. Nonetheless,
SCD rates for those with LVEF >35% in the first year
after MI remain at approximately 3% (equivalent to
placebo annual arrhythmic death rate in SCD-HeFT).
With appropriate risk stratification methods (for exam-
ple, a combination of class 3 CHF, fragmented QRS,
electrophysiology study, MRI, etc.), it is quite plausible
to identify a population at higher SCD risk compared to
existing primary prevention ICD patients.
& Heart failure with normal ejection fraction (HFNEF).
Approximately 50% of patients with congestive heart
failure have normal or near-normal LVEF [35]. The
proportion of deaths due to ventricular arrhythmia in
this group is likely significantly less than in heart failure
with impaired LVEF. In fact, in the Duke database, the
rate of SCD was 0.5% per year for patients with
HFNEF [36]. However, several independent predictors
of SCD were identified which, together with screening
biomarkers or genetic studies, could identify patients at
sufficient risk for ICD-based primary prevention. This
group is important to target since one half of all SCDs
occur in patients with normal LVEF [9, 11].
& Non-ischemic cardiomyopathy LVEF >35%. Although
sudden death rates are too low to warrant ICD
prevention in this overall group, there may be sub-
populations at sufficiently high risk to benefit from
primary prevention ICD use. Risk stratification methods
are not well developed, but this group will be important
to target for prevention for the estimated 20% or so of
patients who have SCD without significant coronary
artery disease [22].
Regardless of high arrhythmic event or SCD rates in
observational studies, randomized clinical trials will be
necessary to prove ICD benefit in individual population
subgroups. While measuring arrhythmic events increases
the power of an observational study, SCD rates are
substantially lower than arrhythmic event rates due to the
often non-sustained nature of ventricular arrhythmias. Even
high observed SCD rates do not ensure benefit from ICDs.
Improvements in SCD rates can be completely offset by
increases in competing causes of mortality [15, 32, 37]. To
the degree that competing mortality is driven by progres-
sive heart failure/pump failure, use of ICDs with biven-
tricular pacing capability may further improve ICD
efficacy. The economic viability of any prevention strategy
using ICDs will be dependent not only on magnitude of
mortality benefit, but also cost of the ICD systems used. In
general, physicians and medical device manufacturers have
favored the use of ICDs with maximal functionality (and
higher costs). Clinical trials utilizing less expensive devices
in lower risk patient populations could expand SCD
prevention. However, any such strategy would be subject
to physician, patient (and sometimes legal) bias toward high
technology–high cost medicine.
6 Conclusions
Left ventricular systolic dysfunction has served for many
years as an important tool for SCD risk identification and
subsequent prevention efforts. While it continues to benefit
a subgroup of patients at risk of SCD, the predictive ability
of this test among overall patients at risk for SCD has been
overestimated. A continued, aggressive search for novel
predictors other than LVEF is warranted using a pathophy-
siologically targeted approach. Development of tests to
refine SCD risk stratification and the conduct of trials to
translate these to clinical practice will require more ongoing
effort and expense. However, in the long run, these ongoing
efforts are the answer to optimizing the utilization of an
important preventive intervention such as the ICD, and
preventing premature death due to SCD.
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